Stoke Therapeutics Inc

NASDAQ:STOK  
20.31
-3.54 (-14.84%)
Earnings Announcements

Stoke Therapeutics Reports Third Quarter Financial Results And Provides Business Updates

Published: 11/08/2021 12:13 GMT
Stoke Therapeutics Inc (STOK) - Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates.
Q3 Loss per Share $0.61.
Cash, Cash Equivalents, Marketable Securities and Restricted Cash is Anticipated to Fund Operations Until End of 2023.
Q3 Earnings per Share View $-0.59 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.61

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.65

More details on our Analysts Page.